AnaptysBio, Inc
(NASDAQ:ANAB)

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various derma...

Website: http://www.anaptysbio.com

Founded: 2005

Full Time Employees: 89

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31

collaboration revenue	25,556,000	108,249,000	76,320,000	22,263,000	27,771,000	43,113,000	30,017,000	10,971,000	7,179,000	9,005,000	3,318,000	3,460,000	1,374,000	6,808,000	1,293,000	1,216,000	970,000	1,011,000	20,890,000	30,027,000	11,247,000	60,000,000			15,000,000	3,000,000		5,000,000			5,000,000			3,000,000		7,000,000
operating expenses:
research and development	33,991,000	25,559,000	31,407,000	37,824,000	41,180,000	42,589,000	42,212,000	41,997,000	37,042,000	33,525,000	30,878,000	32,923,000	34,957,000	23,374,000	22,064,000	20,844,000	22,516,000	26,776,000	22,221,000	25,314,000	24,185,000	21,567,000	19,542,000	17,948,000	20,968,000	21,426,000	29,931,000	27,350,000	20,631,000	15,920,000	17,883,000	10,583,000	11,810,000	7,606,000	6,697,000	7,205,000	7,935,000
general and administrative	26,202,000	15,789,000	10,209,000	10,609,000	14,130,000	10,194,000	10,562,000	9,295,000	12,338,000	10,276,000	10,172,000	10,680,000	10,818,000	9,407,000	8,862,000	8,171,000	10,203,000	5,392,000	5,432,000	5,246,000	5,423,000	5,088,000	4,794,000	4,687,000	4,285,000	3,832,000	3,814,000	4,307,000	4,141,000	3,743,000	4,004,000	3,832,000	3,947,000	2,545,000	2,390,000	2,350,000	2,053,000
total operating expenses	60,193,000	41,348,000	41,616,000	48,433,000	55,310,000	52,783,000	52,774,000	51,292,000	49,380,000	51,140,000	41,050,000	43,603,000	45,775,000	32,781,000	30,926,000	29,015,000	32,719,000	32,168,000	27,653,000	30,560,000	29,608,000	26,655,000	24,336,000	22,635,000	25,253,000	25,258,000	33,745,000	31,657,000	24,772,000	19,663,000	21,887,000	14,415,000	15,757,000	10,151,000	9,087,000	9,555,000	9,988,000
income from operations	-34,637,000	66,901,000	34,704,000	-26,170,000	-27,539,000	-9,670,000	-22,757,000	-40,321,000	-42,201,000	-42,135,000	-37,732,000	-40,143,000	-44,401,000	-25,973,000	-29,633,000	-27,799,000	-31,749,000	-31,157,000	-6,763,000	-533,000	-18,361,000	33,345,000	-24,336,000	-22,635,000	-10,253,000	-22,258,000	-33,745,000	-26,657,000	-24,772,000	-19,663,000	-16,887,000	-14,415,000	-15,757,000	-7,151,000	-9,087,000	-2,555,000	-9,988,000
yoy	25.77%	-791.84%	-252.50%	-35.10%	-34.74%	-77.05%	-39.69%	0.44%	-4.95%	62.23%	27.33%	44.40%	39.85%	-16.64%	338.16%	5115.57%	72.92%	-193.44%	-72.21%	-97.65%	79.08%	-249.81%	-27.88%	-15.09%	-58.61%	13.20%	99.83%	84.93%	57.21%	174.97%	85.84%	464.19%	57.76%
qoq	-151.77%	92.78%	-232.61%	-4.97%	184.79%	-57.51%	-43.56%	-4.45%	0.16%	11.67%	-6.01%	-9.59%	70.95%	-12.35%	6.60%	-12.44%	1.90%	360.70%	1168.86%	-97.10%	-155.06%	-237.02%	7.51%	120.76%	-53.94%	-34.04%	26.59%	7.61%	25.98%	16.44%	17.15%	-8.52%	120.35%	-21.31%	255.66%	-74.42%
other income, net:
interest income	2,653,000	2,508,000	2,924,000	3,654,000	4,413,000	5,263,000	5,324,000	4,623,000	4,584,000	4,880,000	4,854,000	4,653,000	4,486,000	3,839,000	2,262,000	1,107,000	342,000	68,000	64,000	104,000	195,000	376,000	625,000	1,061,000	1,897,000	2,282,000	2,757,000	2,957,000	2,988,000	2,834,000	1,369,000	1,297,000	1,185,000
non-cash interest expense for the sale of future royalties	-20,859,000	-19,711,000	-22,515,000	-19,606,000	-18,061,000	-17,404,000	-15,413,000	-10,953,000	-6,317,000	-4,958,000	-4,431,000	-4,358,000	-4,336,000	-4,251,000	-6,135,000	-5,868,000	-4,854,000
other income	-1,000	-3,000		3,531,000	1,902,000	21,000	-5,000				1,000	3,000	-4,000	-4,000	4,000	6,000	6,000	1,000	33,000		3,000	-75,000	-56,000	26,000	94,000	-109,000	144,000	-41,000	7,000	8,000	-40,000	-64,000	-63,000	-877,000	449,000	310,000	347,000
total other expense	-18,207,000	-10,939,500	-19,591,000	-12,421,000	-11,746,000
income before income taxes	-52,844,000	49,695,000	15,113,000	-38,591,000	-39,285,000	-21,790,000	-32,851,000	-46,651,000														33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,285,000	-31,084,000	-24,022,000	-22,097,000
provision for income taxes	-40,000	-20,750		-39,000	-44,000	-2,250		-9,000																		22,000	51,000	60,000	19,000
net income	-52,884,000	49,614,000	15,113,000	-38,630,000	-39,329,000	-21,784,000	-32,851,000	-46,660,000	-43,936,000	-42,211,000	-37,308,000	-39,845,000	-44,255,000	-26,413,000	-33,502,000	-32,554,000	-36,255,000	-32,538,000	-6,666,000	-429,000	-18,163,000	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,263,000	-31,033,000	-23,962,000	-22,078,000	-16,994,000	-15,958,000	-13,618,000	-15,086,000	-6,861,000	-9,090,000	-2,684,000	-11,435,000
yoy	34.47%	-327.75%	-146.00%	-17.21%	-10.49%	-48.39%	-11.95%	17.10%	-0.72%	59.81%	11.36%	22.40%	22.07%	-18.82%	402.58%	7488.34%	99.61%	-196.71%	-71.95%	-98.01%	119.84%	-266.05%	-23.41%	-10.07%	-62.58%	19.24%	94.47%	75.96%	46.35%	147.69%	75.56%	407.38%	31.93%
qoq	-206.59%	228.29%	-139.12%	-1.78%	80.54%	-33.69%	-29.59%	6.20%	4.09%	13.14%	-6.37%	-9.96%	67.55%	-21.16%	2.91%	-10.21%	11.42%	388.12%	1453.85%	-97.64%	-153.98%	-241.57%	10.30%	160.81%	-59.23%	-34.70%	29.51%	8.53%	29.92%	6.49%	17.18%	-9.73%	119.88%	-24.52%	238.67%	-76.53%
other comprehensive loss:
unrealized loss on available-for-sale securities	-122,000
comprehensive loss	-53,006,000			-38,797,000	-39,473,000	-22,238,000	-31,677,000	-46,451,000	-43,763,000	-40,658,000	-36,047,000	-40,189,000	-42,276,000	-25,652,000	-35,648,000	-33,981,000	-38,267,000	-32,760,000	-6,690,000	-494,000	-18,270,000	33,383,000	-24,261,000	-21,940,000	-7,455,000	-20,405,000	-31,127,000	-23,592,000	-21,651,000	-16,676,000	-15,822,000	-13,494,000	-15,887,000	-7,244,000	-9,074,000		-11,448,000
net loss per common share:
basic and diluted	-1,840			-1,340	-1,280	-660	-1,140	-1,710	-1,640	-1,590	-1,410	-1,500	-1,580	-930	-1,180	-1,150	-1,310	-1,190	-240	-20	-660	1,230	-870	-790	-300	-750	-1,150	-890	-820	-640	-660	-570	-630				-750
weighted-average number of shares outstanding:
basic and diluted	28,691,000	28,758,000		28,810,000	30,644,000	28,382,000	28,893,000	27,356,000	26,801,000	26,924,000	26,546,000	26,629,000	27,953,000	28,165,000	28,289,000	28,204,000	27,713,000	27,431,000	27,436,000	27,391,000	27,361,000	27,302,000	27,316,000	27,279,000	27,264,000	27,059,000	27,058,000	27,026,000	26,981,000	24,673,000	24,146,000	23,932,000	23,801,000	19,782,000			15,295,000
unrealized gain on available for sale securities		-71,000	53,000	-167,000	-144,000	-454,000	1,174,000	209,000	173,000	1,553,000	1,261,000	-344,000	1,979,000
comprehensive income		-15,776,000	15,166,000																																	-2,730,000
net income per common share:
basic		-540	540																																	-130
diluted		-540	520																																	-130
weighted-average number of shares outstanding:
basic			27,833,000																																20,382,000	20,271,000
diluted			29,018,000																																20,382,000	20,271,000
total other income						-12,120,000	-10,094,000	-6,330,000	-1,735,000	-80,000	424,000	298,000	146,000	-416,000	-3,869,000	-4,755,000	-4,506,000	-1,381,000	97,000	104,000	198,000	301,000	569,000	1,087,000	1,991,000	1,973,000	2,661,000	2,635,000	2,675,000	2,477,000	929,000	797,000	671,000	290,000	-3,000	-129,000	-1,447,000
other expense									-2,000
unrealized loss on available for sale securities														761,000	-2,146,000	-1,427,000	-2,012,000	-49,000	-24,000														-801,000			-46,000	-13,000
unrealized income on available for sale securities																				-65,000	-107,000									373,000	136,000	124,000		-10,750	16,000
interest expense																										-200,000	-240,000	-281,000	-320,000	-365,000	-400,000	-436,000	-451,000	-456,000	-452,000	-439,000	-428,000
other comprehensive income:
unrealized income on available for sale securities, net of tax of 0, (25), 0 and 189, respectively																						-19,750	-494,000
unrealized income on available for sale securities, net of tax of 0, 99, 0 and 214, respectively																								-392,000
unrealized income on available for sale securities, net of tax of 0 and 115, respectively																									807,000
unrealized income on available for sale securities, net of tax of (25), 0, 189 and 0, respectively																										175,750	-94,000
unrealized income on available for sale securities, net of tax of 99, 0, 214 and 0, respectively																												370,000
unrealized income on available for sale securities, net of tax of 115 and 0, respectively																													427,000
change in fair value of liability for preferred stock warrants																																					-1,366,000
other comprehensive income																														-28,750	136,000	124,000		-10,750	16,000
other comprehensive loss																																	-801,000			-46,000	-13,000
net income attributed to participating securities
net loss attributed to common stockholders																																		-5,802,250	-9,090,000
net loss per common share:
basic																																		-310	-450
diluted																																		-310	-450
net income attributed to common stockholders																																				-2,684,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31

assets
current assets:
cash and cash equivalents	248,469,000	238,196,000	109,833,000	44,298,000	98,637,000	123,080,000	191,581,000	71,821,000	53,695,000	35,965,000	26,295,000	35,206,000	94,562,000	71,308,000	58,547,000	71,701,000	166,412,000	495,729,000	336,328,000	332,254,000	284,148,000	250,456,000	209,154,000	221,172,000	165,317,000	171,017,000	182,898,000	146,552,000	105,853,000	113,596,000	293,408,000	57,057,000	69,474,000	81,189,000	26,669,000	30,752,000	96,754,000	51,232,000
receivables from collaborative partners	25,747,000	33,850,000	75,685,000	21,418,000	17,884,000	40,765,000	12,195,000	9,007,000	7,089,000	6,851,000	3,269,000	3,182,000	1,523,000	1,419,000	1,180,000	1,033,000	921,000	876,000	761,000
short-term investments	37,986,000	73,442,000	139,123,000	221,412,000	241,299,000	262,293,000	238,536,000	278,983,000	300,970,000	354,939,000	386,752,000	394,280,000	336,589,000	369,933,000	384,419,000	370,450,000	339,209,000	52,368,000	37,736,000	58,597,000	96,212,000	143,197,000	129,192,000	156,706,000	197,166,000	203,210,000	238,104,000	275,664,000	309,812,000	313,486,000	200,406,000	210,852,000	178,691,000	167,218,000	89,053,000	75,607,000	6,742,000
prepaid expenses and other current assets	3,907,000	4,762,000	6,009,000	4,778,000	5,292,000	5,738,000	6,369,000	7,539,000	10,666,000	9,080,000	11,684,000	5,867,000	4,480,000	4,545,000	6,298,000	9,625,000	5,869,000	4,903,000	11,759,000	6,508,000	5,464,000	2,908,000	7,468,000	6,638,000	3,572,000	3,506,000	3,595,000	3,772,000	6,102,000	6,960,000	4,035,000	3,758,000	2,170,000	2,688,000	3,119,000	3,852,000	1,694,000	1,633,000
total current assets	316,109,000	350,250,000	330,650,000	291,906,000	363,112,000	431,876,000	448,681,000	367,350,000	372,420,000	406,835,000	428,000,000	438,535,000	437,154,000	447,205,000	450,444,000	452,809,000	512,411,000	553,876,000	386,644,000	398,061,000	387,131,000	396,561,000	345,814,000	384,516,000	371,055,000	377,733,000	424,597,000	430,988,000	421,942,000	434,216,000	503,022,000	271,819,000	251,945,000	252,696,000	120,327,000	115,848,000	110,155,000	58,208,000
property and equipment	1,280,000	1,370,000	1,500,000	1,628,000	1,741,000	1,849,000	1,728,000	1,833,000	1,954,000	2,098,000	2,254,000	2,023,000	1,982,000	2,089,000	1,972,000	2,059,000	2,162,000	2,283,000	2,413,000	2,488,000	1,754,000	1,783,000	1,585,000	1,495,000	1,610,000	1,618,000	1,695,000	1,481,000	1,584,000	1,445,000	1,344,000	1,086,000	659,000	665,000	513,000	543,000	569,000	471,000
operating lease right-of-use assets	12,039,000	12,519,000	12,994,000	13,464,000	13,923,000	14,383,000	14,839,000	15,291,000	15,732,000	16,174,000	16,613,000	17,047,000	17,471,000	17,898,000	18,320,000	18,739,000	19,147,000	19,558,000	19,778,000	20,278,000
other long-term assets	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	256,000	258,000	258,000	477,000	602,000	1,114,000	1,354,000	1,293,000	1,481,000	1,735,000	1,913,000	2,089,000	148,000	79,000	322,000	289,000
total assets	329,684,000	364,395,000	353,098,000	335,250,000	422,053,000	483,834,000	493,418,000	427,376,000	405,835,000	452,389,000	487,326,000	517,100,000	551,792,000	610,383,000	618,503,000	603,848,000	625,171,000	643,070,000	424,335,000	426,569,000	396,418,000	416,552,000	384,750,000	401,746,000	424,233,000	435,197,000	451,505,000	480,149,000	494,226,000	508,997,000	523,121,000	306,017,000	314,837,000	329,364,000	121,945,000	130,409,000	131,111,000	62,180,000
liabilities and stockholders’ equity
current liabilities:
accounts payable	7,517,000	3,871,000	2,893,000	3,329,000	6,123,000	4,002,000	3,592,000	4,890,000	4,582,000	4,698,000	6,521,000	4,761,000	3,168,000	2,784,000	3,006,000	1,587,000	2,481,000	1,741,000	5,717,000	4,103,000	2,452,000	4,217,000	5,484,000	6,289,000	8,571,000	16,237,000	10,522,000	10,921,000	9,072,000	5,443,000	6,180,000	4,426,000	2,416,000	2,323,000	2,557,000	3,724,000	2,546,000	2,278,000
accrued expenses	32,065,000	32,674,000	33,171,000	30,197,000	35,952,000	39,501,000	38,401,000	33,680,000	25,903,000	30,967,000	30,916,000	35,164,000	30,956,000	21,633,000	16,453,000	16,714,000	15,763,000	12,853,000	14,075,000	15,958,000	11,826,000	15,262,000	18,139,000	12,916,000	13,781,000	11,052,000	15,286,000	14,102,000	8,400,000	8,761,000	7,145,000	4,837,000	4,405,000	4,875,000	3,604,000	3,230,000	4,330,000	3,429,000
current portion of operating lease liability	2,120,000	2,080,000	2,040,000	2,001,000	1,962,000	1,925,000	1,887,000	1,850,000	1,813,000	1,777,000	1,741,000	1,706,000	1,671,000	1,637,000	1,604,000	1,570,000	1,537,000	1,505,000	1,097,000	555,000
total current liabilities	41,702,000	38,625,000	38,104,000	35,527,000	44,037,000	45,428,000	43,880,000	40,420,000	32,298,000	37,442,000	39,178,000	41,631,000	35,795,000	26,054,000	21,063,000	19,871,000	19,781,000	16,099,000	20,889,000	20,616,000	14,475,000	19,821,000	24,474,000	20,130,000	23,250,000	29,535,000	29,730,000	30,623,000	24,754,000	21,836,000	20,873,000	16,790,000	14,343,000	14,090,000	11,174,000	10,079,000	8,126,000	5,708,000
liability related to sale of future royalties	263,742,000	276,528,000	331,844,000	331,361,000	330,382,000	353,426,000	350,564,000	361,981,000	310,184,000	310,807,000	311,272,000	310,073,000	307,516,000	304,413,000	301,586,000	261,019,000	255,584,000	251,093,000
operating lease liability, net of current portion	11,493,000	12,032,000	12,566,000	13,095,000	13,613,000	14,112,000	14,607,000	15,096,000	15,575,000	16,037,000	16,493,000	16,946,000	17,388,000	17,813,000	18,235,000	18,652,000	19,059,000	19,450,000	19,838,000	20,222,000
stockholders’ equity:
preferred stock, 0.001 par value...
common stock, 0.001 par value...	29,000	28,000	28,000	28,000	30,000	30,000	30,000	27,000	27,000	27,000	27,000	27,000	27,000	29,000	28,000	28,000	28,000	28,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	27,000	24,000	24,000	24,000	20,000	20,000	20,000	3,000
additional paid-in capital	838,307,000																						657,560,000
accumulated other comprehensive loss	-146,000							-415,000	-624,000	-797,000	-2,350,000	-3,611,000	-3,267,000	-5,246,000	-6,007,000	-3,861,000	-2,434,000	-422,000	-200,000	-176,000	-111,000									-223,000	-541,000	-677,000	-801,000	-426,000	-43,000	-59,000
accumulated deficit	-825,443,000	-772,559,000	-822,173,000	-837,286,000	-798,656,000	-759,327,000	-737,543,000	-704,692,000	-658,032,000	-614,096,000	-571,885,000	-534,577,000	-494,732,000	-450,477,000	-424,064,000	-390,562,000	-358,008,000	-321,753,000	-289,215,000	-282,549,000	-282,120,000	-263,957,000	-297,603,000	-273,836,000	-252,288,000	-244,026,000	-223,763,000	-192,730,000	-168,768,000	-146,690,000	-129,696,000	-113,738,000	-100,120,000	-85,034,000	-78,173,000	-69,083,000	-66,399,000	-54,923,000
total stockholders’ equity	12,747,000	37,210,000			34,021,000	70,868,000	84,367,000	9,879,000	47,778,000	88,103,000	120,383,000	148,450,000	191,093,000	262,103,000	277,619,000	304,306,000	330,747,000	356,428,000	383,608,000	385,731,000	381,943,000	396,731,000	360,243,000	381,436,000	400,564,000	405,008,000	420,892,000	448,421,000	468,155,000	486,365,000	499,677,000	284,979,000	294,527,000	307,581,000	101,355,000	109,175,000	110,115,000
total liabilities and stockholders’ equity	329,684,000	364,395,000		335,250,000	422,053,000	483,834,000	493,418,000	427,376,000	405,835,000	452,389,000	487,326,000	517,100,000	551,792,000	610,383,000	618,503,000	603,848,000	625,171,000	643,070,000	424,335,000	426,569,000	396,418,000	416,552,000	384,750,000	401,746,000	424,233,000		451,505,000	480,149,000	494,226,000
long-term investments			7,698,000	27,996,000	43,021,000	35,470,000	27,914,000	42,646,000	15,473,000	27,026,000	40,203,000	59,239,000	94,929,000	142,935,000	147,511,000	129,985,000	91,195,000	67,097,000	15,242,000	5,484,000	7,056,000	17,546,000	36,177,000	14,321,000	50,215,000	54,305,000	23,418,000	45,707,000	68,551,000	73,128,000	18,616,000	32,730,000	61,884,000	75,897,000	999,000	13,912,000	20,327,000
additional paid in capital		809,765,000	792,682,000	792,531,000	832,486,000	829,860,000	821,121,000	714,959,000	706,407,000	702,969,000	694,591,000	686,611,000	689,065,000	717,797,000	707,662,000	698,701,000	691,161,000	678,575,000	672,996,000	668,429,000	664,147,000	660,665,000		654,492,000	651,680,000	648,669,000	644,148,000	640,550,000	636,692,000	633,251,000	629,887,000	399,370,000	395,424,000	393,017,000	179,551,000	178,297,000	176,507,000	16,672,000
accumulated other comprehensive gain		-24,000	47,000	-6,000	161,000	305,000	759,000
stockholders’ (deficit) equity:
total stockholders’ (deficit) equity			-29,416,000	-44,733,000
total liabilities and stockholders’ (deficit) equity			353,098,000
long-term restricted cash
short-term restricted cash																			60,000
receivable from collaborative partners																				642,000	1,247,000				5,000,000			5,000,000			5,000,000							1,225,000
restricted cash																				60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000	60,000
other current liabilities																					197,000	342,000	851,000	925,000	898,000	871,000	845,000	819,000	794,000	58,000	48,000	27,000	22,000	17,000	13,000			1,000
notes payable, current portion																										1,375,000	3,077,000	4,781,000	6,488,000	7,574,000	7,500,000	7,500,000	7,500,000	6,875,000	5,000,000	3,125,000	1,250,000
other long-term liabilities																							33,000	180,000	419,000	654,000	883,000	1,105,000	1,317,000
accumulated other comprehensive income																						-4,000	259,000	753,000	1,145,000	338,000	480,000	574,000	204,000								-13,000
australian tax incentive receivable																													175,000	174,000	173,000	152,000	1,610,000	1,601,000	1,486,000	5,637,000	4,965,000	4,118,000
total liabilities, preferred stock and stockholders’ equity																										435,197,000				508,997,000	523,121,000	306,017,000	314,837,000
liabilities, preferred stock andstockholders’ equity
notes payable, net of current portion																														625,000	2,409,000	4,120,000	5,834,000	7,553,000	9,269,000	10,987,000	12,709,000	13,809,000
deferred rent																														171,000	162,000	128,000	133,000	140,000	147,000	168,000	161,000	154,000
liabilities, preferred stock and stockholders’ equity
long-term vendor deposits																																		46,000	46,000	46,000
deferred financing costs																																						3,441,000
liabilities, convertible preferred stock andstockholders’ equity
preferred stock warrant liabilities																																						3,241,000
commitments and contingencies
series b convertible preferred stock, 0.001 par value...																																						28,220,000
series c convertible preferred stock, 0.001 par value...																																						6,452,000
series c-1 convertible preferred stock, 0.001 par value...																																						2,156,000
series d convertible preferred stock, 0.001 par value...																																						40,688,000
stockholders’ equity
total liabilities, convertible preferred stock and stockholders’ equity																																		329,364,000	121,945,000	130,409,000	131,111,000
liabilities, convertible preferred stock and stockholders’ deficit
deferred revenue
income taxes payable
stockholders’ deficit:
total stockholders’ deficit																																						-38,248,000
total liabilities, convertible preferred stock and stockholders’ deficit																																						62,180,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31

cash flows from operating activities:
net loss	-52,884,000	49,614,000	15,113,000	-38,630,000	-39,329,000	-21,784,000	-32,851,000	-46,660,000	-43,936,000	-42,211,000	-37,308,000	-39,845,000	-44,255,000			-32,554,000	-36,255,000	-32,538,000	-6,666,000	-429,000	-18,163,000	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,263,000	-31,033,000	-23,962,000	-22,078,000	-16,994,000	-15,958,000	-13,618,000	-15,086,000				-11,435,000
adjustments to reconcile net loss to net cash from operating activities:
depreciation and amortization	130,000	131,000	140,000	142,000	146,000	145,000	144,000	154,000	163,000	165,000	158,000	163,000	166,000	184,000	166,000	163,000	162,000	165,000	169,000	160,000	125,000	144,000	138,000	137,000	140,000	140,000	135,000	124,000	115,000	106,000	91,000	64,000	54,000	47,000	46,000	51,000	39,000
stock-based compensation	14,218,000	8,506,000	9,157,000	9,239,000	9,170,000	8,184,000	8,189,000	7,544,000	10,131,000	8,111,000	7,807,000	8,427,000	8,860,000	6,685,000	6,271,000	6,658,000	7,742,000	3,978,000	4,364,000	3,690,000	3,315,000	2,978,000	2,805,000	2,741,000	2,975,000	2,757,000	3,144,000	3,643,000	2,867,000	2,621,000	2,532,000	2,548,000	2,260,000	1,132,000	942,000	1,438,000	866,000
accretion/amortization of investments	-8,000	-340,000	-1,130,000	-1,597,000	-1,667,000	-2,302,000	-2,566,000	-2,477,000	-2,968,000	-3,154,000	-2,993,000	-2,183,000	-2,191,000	-1,723,000			161,000	100,000	100,000	126,000	167,000	222,000	178,000	69,000	-8,000	-184,000	-523,000
amortization of right-of-use assets – operating	480,000	475,000	470,000	459,000	460,000	456,000	452,000	441,000	442,000	439,000	434,000	424,000	427,000	422,000	419,000	408,000	411,000	220,000	500,000
non-cash interest expense for sale of future royalties	20,859,000
changes in operating assets and liabilities:
receivables from collaborative partners	8,103,000	41,835,000	-54,267,000	-3,534,000	22,881,000	-28,570,000	-3,188,000	-1,918,000	-238,000	-3,582,000	-87,000	-1,659,000	-104,000	-239,000	-147,000	-112,000	-45,000	-115,000
prepaid expenses and other assets	1,501,000	971,000	-303,000	414,000	530,000	299,000	1,405,000	3,065,000	-1,566,000	2,843,000	-5,796,000	-1,292,000	51,000	1,705,000	2,821,000	-4,118,000	-1,221,000	6,740,000	-5,306,000	-959,000	-2,276,000	5,008,000	-424,000	-2,711,000	233,000	253,000	490,000	2,649,000	-1,214,000	-3,785,000	-217,000	-1,574,000	388,000	-304,000	909,000	-2,347,000	-143,000
accounts payable and other liabilities	-17,819,000	-22,412,000	-18,561,000	-22,320,000	-24,034,000	-40,047,000	3,364,000	8,018,000	-5,172,000	-1,498,000	-2,702,000	6,605,000	8,533,000	4,832,000	1,257,000	75,000	3,536,000	-5,321,000	-191,000	5,897,000	-5,125,000	-4,446,000	4,057,000	-3,298,000	-5,190,000	1,319,000	520,000	7,584,000	5,076,000	1,137,000	3,849,000	2,255,000	-158,000	1,137,000	-1,019,000	1,418,000	682,000
deferred income					3,544,000
operating lease liabilities	-499,000	-494,000	-490,000	-479,000	-462,000	-457,000	-452,000	-442,000	-426,000	-420,000	-418,000	-407,000	-391,000	-389,000	-383,000	-374,000	-359,000	20,000	158,000
net cash from operating activities	-25,919,000	97,997,000	-27,356,000	-40,244,000	-10,700,000	-66,672,000	-10,090,000	-21,322,000	-37,253,000	-34,349,000	-36,474,000	-25,409,000	-24,568,000	-10,685,000	-17,747,000	-24,147,000	-21,014,000	-25,301,000	-7,006,000	9,591,000	-23,204,000	37,578,000	-17,013,000	-19,610,000	-15,112,000	-15,805,000	-22,096,000	-15,517,000	-16,099,000	-12,290,000	-14,860,000	-8,878,000	-12,478,000	-4,810,000	-3,888,000	-2,643,000	-8,097,000
capital expenditures	-17,000	-1,000	-12,000	-39,000	-35,000	-263,000	-35,000	-33,000	-27,000	-280,000	-162,000	-190,000	-175,000	-175,000	-50,000	-78,000	-55,000	-14,000	-172,000	-863,000	-317,000	-311,000	-88,000	-83,000	-87,000	-104,000	-280,000	-241,000	-180,000	-206,000	-321,000	-304,000	-232,000	-124,000	-13,000	-68,000	-85,000
free cash flows	-25,936,000	97,996,000	-27,368,000	-40,283,000	-10,735,000	-66,935,000	-10,125,000	-21,355,000	-37,280,000	-34,629,000	-36,636,000	-25,599,000	-24,743,000	-10,860,000	-17,797,000	-24,225,000	-21,069,000	-25,315,000	-7,178,000	8,728,000	-23,521,000	37,267,000	-17,101,000	-19,693,000	-15,199,000	-15,909,000	-22,376,000	-15,758,000	-16,279,000	-12,496,000	-15,181,000	-9,182,000	-12,710,000	-4,934,000	-3,901,000	-2,711,000	-8,182,000
cash flows from investing activities:
purchase of investments
sales and maturities of investments	35,000,000	73,501,000	122,950,000	90,650,000	137,429,000	91,749,000	110,000,000	146,743,000	127,640,000	115,765,000	100,845,000	98,744,000	134,126,000	149,250,000	147,746,000	101,400,000	9,620,000	25,500,000	27,744,000	42,320,000	63,284,000	42,264,000	74,445,000	88,411,000	84,851,000	80,905,000	102,879,000	110,667,000	89,600,000	57,598,000	58,520,000	55,450,000	34,581,000	27,271,000
purchases of property and equipment	-17,000	-1,000	-12,000	-39,000	-35,000	-263,000	-35,000	-33,000	-27,000	-280,000	-162,000	-190,000	-175,000	-175,000	-50,000	-78,000	-55,000	-14,000	-172,000	-863,000	-317,000	-311,000	-88,000	-83,000	-87,000	-104,000	-280,000	-241,000	-180,000	-206,000	-321,000	-304,000	-232,000	-124,000	-13,000	-68,000	-85,000
net cash from investing activities	34,983,000	73,500,000	103,282,000	36,403,000	14,847,000	-29,396,000	58,620,000	-2,442,000	68,616,000	49,178,000	30,635,000	-20,455,000	85,396,000	21,497,000	-32,434,000	-70,996,000	-312,912,000	-66,694,000	10,839,000	37,961,000	56,729,000	3,598,000	4,732,000	75,394,000	10,751,000	4,035,000				-166,150,000	24,615,000	-3,062,000	2,146,000	-153,057,000	-495,000	-62,421,000	-27,085,000
cash flows from financing activities:
proceeds from issuance of common stock	14,021,000	12,212,000	336,000	1,423,000	290,000	555,000	4,128,000	979,000	811,000	264,000	160,000	783,000	1,265,000	3,419,000	2,699,000	865,000	4,844,000
repurchase and retirements of common stock			-9,720,000	-51,098,000	-4,424,000						0	-12,474,000	-37,526,000
payment for net share settlement of equity awards		0	0	0	-1,451,000	0	0	0	-7,504,000
principal repayment of liability for sale of future royalties	-12,812,000	-51,962,000	-1,007,000	-823,000	-23,005,000
net cash from financing activities	1,209,000	-43,134,000	-10,391,000	-50,498,000	-28,590,000	27,567,000	71,230,000	41,890,000	-13,633,000	-5,159,000	-3,072,000	-13,492,000	-37,574,000		37,027,000	432,000	4,609,000		241,000	554,000	167,000	126,000	263,000	71,000	-1,339,000	-111,000	-1,421,000	-1,660,000	-1,301,000	-1,372,000	226,596,000	-477,000	-1,383,000	212,387,000	300,000	-938,000	80,704,000
net increase in cash and cash equivalents	10,273,000	128,363,000	65,535,000	-54,339,000	-24,443,000	-68,501,000	119,760,000	18,126,000	17,730,000				23,254,000		-13,154,000	-94,711,000	-329,317,000
cash and cash equivalents, beginning of period	238,196,000	0	0	0	123,080,000	0	0	0	35,965,000
cash and cash equivalents, end of period	248,469,000	128,363,000	65,535,000	-54,339,000	98,637,000	-68,501,000	119,760,000	18,126,000	53,695,000
supplemental disclosure of cash flow information
interest portion of repayment for sale of future royalties	20,833,000	23,065,000	21,025,000	17,804,000	18,100,000
state income taxes paid	40,000
non-cash investing and financing activities:
amounts accrued for property and equipment	23,000				11,000	3,000				-271,000	227,000	14,000	38,000	126,000			19,000	20,000	-78,000	31,000	58,000	114,000	140,000	-61,000	86,000	-41,000	68,000	-219,000	233,000	-1,000	-34,000	187,000	7,000	179,000	3,000	-43,000	52,000
amounts accrued for repurchase of common stock
receivable related to issuance of common stock, upon exercise of stock options	304,000	-423,000								0	0	-8,000	-43,000	32,000	-9,000
proceeds from public offerings, net of underwriters' fees																														0
proceeds from the sale of future royalties						0	0							0
payments for repurchase of common stock
payments for offering costs						-122,000																										0	-280,000	-102,000	-12,000	-1,086,000	-399,000
payments for issuance costs related to the sale of future royalties
non-cash interest expense			22,515,000	19,606,000	18,061,000		15,413,000	10,953,000	6,317,000	4,958,000	4,431,000	4,358,000	4,336,000	4,251,000	6,135,000	5,868,000	4,854,000									173,000	171,000	168,000	164,000	165,000	164,000	161,000	156,000	159,000	157,000
purchases of investments			-19,656,000	-54,208,000	-122,547,000		-51,345,000	-149,152,000	-58,997,000		-70,048,000	-119,009,000	-48,555,000		-180,130,000	-172,318,000	-322,477,000		-16,748,000
proceeds from public offerings, net of underwriters’ fees
payments for debt issuance costs							-67,000				0	0	-43,000		-288,000	0	-2,000
income taxes paid			0	39,000	5,000
amounts accrued for repurchases of common stock			74,000	-479,000	959,000						-13,000	-818,000	1,290,000
amounts accrued for offering costs																																		-178,000			1,290,000
amounts accrued for issuance costs related to the sale of future royalties														56,000	-104,000	0	128,000
repayment of liability for sale of future royalties							-26,830,000	-9,053,000	-6,940,000	-5,423,000	-3,232,000	-1,801,000	-1,270,000	-1,424,000	-384,000	-433,000	-233,000
gain on disposal of property and equipment
proceeds from the sale of property and equipment																		0
net increase in cash, cash equivalents, and restricted cash																		159,341,000	4,074,000	48,106,000	33,692,000	41,302,000	-12,018,000			-11,881,000	36,346,000			-179,812,000			-11,715,000				45,522,000
cash, cash equivalents and restricted cash, beginning of period										0	0	0	71,308,000	0	0	0	495,729,000	0	0	0	250,516,000	0	0	0	171,077,000	0	0	0	113,656,000	0	0	0	81,249,000	0	0	0	51,292,000
cash, cash equivalents and restricted cash, end of period										9,670,000	-8,911,000	-59,356,000	94,562,000	12,761,000	-13,154,000	-94,711,000	166,412,000	159,341,000	4,074,000	48,106,000	284,208,000	41,302,000	-12,018,000	55,855,000	165,377,000	-11,881,000	36,346,000	40,699,000	105,913,000	-179,812,000	236,351,000	-12,417,000	69,534,000	54,520,000	-4,083,000	-66,002,000	96,814,000
leased assets obtained in exchange for operating lease liabilities																		0	0
net decrease in cash and cash equivalents											-8,911,000
loss on disposal of property and equipment, net of gain on lease termination
payments on notes payable																						0	0	0	-1,375,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,250,000
net cash provided (used in) by financing activities
interest paid																						0	0	0	4,000	40,000	83,000	129,000	172,000	208,000	250,000	288,000	297,000	327,000	293,000	191,000	278,000
net income																																			-9,090,000
adjustments to reconcile net income to net cash from operating activities:
australian tax incentive receivable																										0	0	175,000	-1,000	-1,000	-21,000	1,458,000	-9,000	-115,000	4,151,000	-672,000	-847,000
proceeds from issuance of common stock, upon the exercise of stock options																			241,000	554,000	167,000	126,000	263,000	71,000	36,000	1,764,000	454,000	215,000	574,000	731,000	669,000	1,397,000	72,000	165,000	311,000	148,000	355,000
receivable from collaborative partners																				605,000	-1,247,000				-5,000,000									0	0	0	1,225,000
acquisition of investments																					-6,238,000	-38,355,000	-69,625,000	-12,934,000	-74,013,000	-76,766,000	-42,736,000	-52,550,000	-79,763,000	-223,542,000	-33,584,000	-58,208,000	-32,203,000	-180,204,000	-21,348,000	-62,353,000	-27,000,000
income taxes
proceeds from issuance of common stock, upon the exercise of warrants																														0	0	1,000	75,000	0	1,000	0	535,000
net decrease in cash, cash equivalents, and restricted cash																									-5,700,000				-7,743,000						-4,083,000
change in fair value of liability for preferred stock warrants																																		0	0	0	1,366,000
reclassification of warrants to equity																																		0	0	0	4,607,000
proceeds for offering costs
net from investing activities
accretion of discount on investments																													-1,028,000
net provided by investing activities																													9,657,000
loss from investments																														-678,000			-83,000
loss on disposal of property and equipment
deferred revenue
proceeds from debt
fair value of warrants issued with debt
income from investments																																		-5,000
income taxes payable
proceeds from the issuance of preferred stock, net of issuance cost
noncash investing and financing activities:
proceeds from initial public offering, net of underwriters fees																																			0	0	80,213,000
noncash interest expense																																					150,000
restricted cash
proceeds from sale of property and equipment
proceeds from the issuance of preferred stock, net of issuance costs
payments for deferred offering costs
amounts accrued for deferred financing costs
conversion of convertible promissory notes payable to related parties into shares of series c-1 preferred stock

AnaptysBio, Inc(NASDAQ:ANAB)

AnaptysBio, Inc
(NASDAQ:ANAB)